Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
68 NC counties are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Closings
118 closings/delays reported, including Durham and Wake public schools.
Just In
Helene update: Category 4 storm continues gaining strength with 140 mph winds as it nears Florida. Tornado watches issued for southern NC counties
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,039.96
+8.81 (+0.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
March 12, 2024
$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
March 11, 2024
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
March 01, 2024
Via
Benzinga
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
February 27, 2024
Via
Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
February 22, 2024
Via
Benzinga
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
March 09, 2024
Good news could be in store for all three of these drugmakers.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
March 08, 2024
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in March
March 08, 2024
These stocks are worth buying in most months of the year.
Via
The Motley Fool
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
March 08, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
2 No-Brainer Biotech Stocks to Buy Right Now
February 21, 2024
These stocks are used to beating the market.
Via
The Motley Fool
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 2/20 Morning Trading
February 20, 2024
Via
Investor Brand Network
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today
February 06, 2024
Via
Benzinga
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
February 26, 2024
Via
Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
February 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
February 21, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests
February 20, 2024
The FDA put studies in eczema and asthma treatment on clinical hold.
Via
Investor's Business Daily
Exposures
Product Safety
Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
February 20, 2024
The Nasdaq 100 closed lower by over 150 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
2 Top Growth Stocks to Buy With $1,000 Right Now
February 18, 2024
Even a modest starting investment in the right stocks could pay off in the years ahead.
Via
The Motley Fool
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
February 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
February 09, 2024
There's room for multiple winners in the fast-growing weight-loss market.
Via
The Motley Fool
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition
February 06, 2024
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Regeneron Announces Investor Conference Presentations
February 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
February 06, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.
Via
Benzinga
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know
February 06, 2024
Via
Benzinga
Stock-Split Watch: Could These 2 Market-Beaters Be Next?
February 06, 2024
Investors might continue bidding up shares of these companies regardless.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.